Advertisement

May 4, 2020

Zoll TherOx Receives CE Mark Approval for SuperSaturated Oxygen Therapy

May 4, 2020—Zoll Medical Corporation, an Asahi Kasei Group Company, announced that it has received CE Mark approval to market and distribute its supersaturated oxygen (SSO2) therapy system in Europe.

SSO2 therapy was developed by TherOx, Inc., which was acquired by Zoll in June 2019. TherOx announce FDA approval for the system in April 2019.

According to the company, SSO2 therapy provides interventional cardiologists with a treatment beyond percutaneous coronary intervention (PCI) to significantly reduce muscle damage in heart attack patients. The system delivers hyperbaric levels of oxygen directly to the damaged heart muscle immediately after successful revascularization via angioplasty and stenting of the blocked coronary artery. It is indicated for patients with left anterior descending ST-elevation myocardial infarction (LAD STEMI) who are treated within 6 hours of symptom onset.

“I am very happy to know that Zoll received CE Mark approval for the TherOx system,” commented Antonio L. Bartorelli, MD, in the company's announcement. Dr. Bartorelli is Interventional Cardiology Director at Centro Cardiologico Monzino, University of Milan in Milan, Italy. He continued, “We were among the first in Europe to observe the beneficial impact of SSO2 therapy on left ventricular recovery after PCI in patients with LAD STEMI and we look forward to being able to use this effective treatment again in our patients.”

Advertisement


May 4, 2020

Large-Scale FOURNIER Study Supports Neurocognitive Safety of Evolocumab Plus Statin to Achieve Very Low LDL-C

May 4, 2020

Cardiovascular Societies Outline a Framework for Resuming Cardiovascular Procedures and Diagnostic Tests